## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

)Attorney Docket No. 3391/US

)Group Art Unit: 1614

)Examiner: Unknown

plication of T. Rogers

Serial No. 09/963,927

Filed: September 26, 2001

For: Hydroxy Acid Integrin Antagonists

Assistant Commissioner of Patents Washington, D.C. 20231

SIR:

INFORMATION DISCLOSURE STATEMENT

In accordance with 37 C.F.R. 1.97 and 1.98 and MPEP 609, and in compliance with the duty of disclosure set forth in 37 C.F.R. 1.56, applicants submit herewith a document cited on the attached Form PTO 1449. Applicants direct the Examiner to the related application(s) for documents previously submitted. Applicants respectfully request that the Examiner consider and enter the document cited on the enclosed Form PTO 1449 into the file of the above-identified application. Applicants also request an indication of the same by return of the Form PTO 1449 being initialed and dated by the Examiner.

Please charge the fee of \$180.00 as required by 37 C.F.R. § 1.17(p) to Deposit Account No. 19-1025. No additional fees are believed due to ensure consideration of the attached documents by the Examiner. However, if any additional fees are required or an overpayment of fees made, the Commissioner is hereby authorized to debit or credit our Deposit Account No. 19-1025, as necessary.

Respectfully submitted,

Rachel A. Polster, Agent Registration No. 47,004 (314) 694-7354 (St. Louis)

Pharmacia Corporation Corporate Patent Department 800 North Lindbergh Boulevard – O4E St. Louis, MO 63167

10/22/2002 EHAILE1 00000083 191025 09963927

01 FC:1806

180.00 CH

RECEIVEL

OCT 2 2 2002

TECH CENTER 1800/900



## CERTIFICATE OF MAILING BY FIRST CLASS MAIL (37 CFR 1.8)

Serial No. 09/963,927

Filing Date: September 26, 2001

Examiner: Unknown
Group Art Unit: 1614
Docket No: 3391/US

Docket No: 3391/US Invention: Hydroxy Acid Integrin Antagonists

Date of Deposit: October 17, 2002

I hereby certify that these papers or fee is being deposited with the United States Post Office to Addressee service under 37 CFR 1.10 & 1.8 on the date indicated above and is addressed to the Commissioner for Patents, Washington, D.C. 20231

Information Disclosure Statement PTO-1449 Copy of International Search Report Copy of References Fee Transmittal Return Post Card

Linda Haley
(Typed or printed name of person mailing paper or fee)

(Signature of person amailing paper or fee)

Sheet 1 of 2

FORM PTO-1449

U.S. DEPARTMENT OF

COMMERCE, PATENT AND TRADEMARK OFFICE

ATTY. DOCKET

APPLICATION NO.:

NO.: S03391

09/963,927

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

INVENTOR: Thomas Rogers, et al.

Filed: Sept. 26, 2001

Group: 1614

## U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
_	1	5602155	02/11/1997	Ruminiski	514	357	01/17/1995
	2	6013651	01/11/2000	Rogers, et al.	514	269	03/04/1998:
	3	6028223	02/22/2000	Ruminski, et al.	564	27	08/27/1996
	4	6211191	04/03/2001	Duggan, et al.	514	274	12/15/1998
	<u> </u>						:

## FOREIGN PATENT DOCUMENTS

Examiner							Trans	lation
Initial		Document Number	Date	Country	Class	Subclass	Yes	No
	5	WO 97/08145	06.03.1997	US	C07D	213/55	X	:
								:

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Examiner Initial		
	6	Carron, et al., Cancer Research; V. 58, No. 9: pp 1930-1935; 1998
	7	Lark, et al., Journal of Bone & Mineral Research; V. 16, No. 2: pp 319-327; 2000
	8	Healy, et al., Human Reproductive Update; V. 4: pp 136; 1998
	9	Cheresh, Cancer Metastasis Review; V. 10: pp 3-10; 1991
	10	Brooks, et al., Cell; V. 79, No. 7: pp 1157-1164; 1994
	11	Friedlander, et al., <i>Prooceedings of the National Academy of Science USA</i> ; V. 93, No. 18; pp 9764-9769; 1996
	12	Badger, et al., Arthritis & Rheumatism; V. 44, No. 1: pp 128-137; 2001
	13	Brown, Cardiovascular Research; V. 28: pp 1815-; 1994
	14	Friedlander, et al., Science; V. 270 (5241): pp 1500-1502; 1995
	15	Agrez, et al., Journal of Cell Biology; V. 127, No. 2: pp 547-556; 1994
	16	Christofidou-Solomidou, et. al., American Journ. Of Pathology; V.151 (4): pp 975-983;1997

EXAMINER DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED (Form PTO-1449)

UCI 2 2 2002

ORM PTO-1449 ATTY. DOCKET APPLICATION NO.: U.S. DEPARTMENT OF COMMERCE, PATENT AND TRADEMARK OFFICE NO.: S03391 09/963,927 INVENTOR: Thomas Rogers, et al. INFORMATION DISCLOSURE STATEMENT BY APPLICANT Filed: Sept. 26, 2001 Group: 1614 (Use several sheets if necessary)

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Examiner Initial		
<u> </u>	17	Seftor, et al., <i>Proceedings of the National Academy of Science USA</i> ; V. 89: pp 1557-1561; March 1992
	18	Montgomery, et al., <i>Proceedings of the National Academy of Science USA</i> ; V. 91: pp 8856-8860; September 1994
	19	Adamis, et al., American Jounal of Ophthalmology; V. 118: pp 445-450; 1994
	20	Peacock, et al., Journal of Experimental Medicine; V. 175: pp 1135-1138; 1992
	21	Brooks, et al., Science; V. 264: pp 569-571; 1994
	22	Sato, et al., Journal of Cell Biology; V. 111: pp 1713-1723; 1990
	23	Fisher, et al., <i>Endocrinology</i> ; V. 132: pp 1411-1413; 1993
	24	Choi, et al., Journal of Vascular Surgery; V. 19 (1): pp 125-134; 1994
	25	White, Current Biology; V. 3 (9): pp 596-599; 1993
	26	Rodriquez, et al., Tetrahedron Letters; V. 32 (7): pp 923-926; 1991
	27	Design in Prodrugs, H. Bundgaard, editor; Elsevier; 1985
	28	Pytela, et al., Methods in Enzymology, V. 144: pp 475-489; 1987
	29	Yatohgo, et al., Cell Structure & Function; V. 13: pp 281-292; 1988
	30	Charo, et al., Journal of Biological Chemistry, V. 266 (3): pp 1415-1421; 1991
	31	Niya, et al., <i>Blood</i> , V. 70 (2): pp 475-483; 1987
	32	Rodbard, et al., International Atomic Energy Agency, Vienna; pp 469-; 1977
	33	Zucker, Methods in Enzymology; V. 169: pp 117-133; 1989

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not through citation if not in conformance and not considered applicant.	. 1
	(Form PTO-1449)



OCT 2 2 2002

TECH CENTER 1600/2900